The Experts below are selected from a list of 527922 Experts worldwide ranked by ideXlab platform
K. Jamal - One of the best experts on this subject based on the ideXlab platform.
-
Smoking cessation care can translate to lower hazard of death in the short-run in cancer patients - a retrospective cohort study to demonstrate the value of smoking cessation services within the Treatment Phase of cancer
BMC cancer, 2019Co-Authors: Feras Hawari, N. A. Obeidat, Dalia Rimawi, K. JamalAbstract:Smoking cessation is a key step towards improving cancer care and outcomes. However, smoking cessation interventions are underprovided in oncology settings. Within Jordan’s only comprehensive oncology center, we sought to evaluate receipt of care at a smoking cessation clinic and the effect of assisted abstinence through the smoking cessation clinic on short-term (two-year) survival after a cancer diagnosis. We employed a retrospective cohort study design. Cancer registry and smoking cessation clinic data for adult Jordanian cancer patients diagnosed between 2009 and 2016, who also were cigarette smokers, and who received full Treatment at King Hussein Cancer Center, were analyzed. Specifically, descriptive statistics of patients who visited the smoking cessation clinic were generated, and short-term (two-year) hazard of death of patients based on whether or not smoking cessation clinic-assisted abstinence occurred, were evaluated. There were 3403 patients who met our inclusion criteria. Approximately 21% of cancer patients were seen at the smoking cessation clinic, and significant demographic and clinical disparities in who was being seen [at the smoking cessation clinic] existed. In 2387 patients with available survival data, smokers who never went to the smoking cessation clinic (or were seen only once, or seen a year or more from diagnosis) had a hazard of death 2.8 times higher than smokers who had visited the smoking cessation clinic and who also confirmed they had not smoked on atleast two of their 3-, 6- or 12-month follow-up visits (95% confidence interval [CI] = 1.7–4.6). Non-abstainers at the smoking cessation clinic exhibited a similar disadvantage (HR 2.7, 95% CI 1.4–5.0). Although evidence-based smoking cessation interventions increase the likelihood of abstinence and can lower the short-term hazard of death during cancer Treatment, there is a deprioritization of smoking cessation interventions during cancer care, as indicated by low proportions of patients seen at the smoking cessation clinic. Our findings emphasize the importance of promoting interventions to avail smoking cessation interventions in oncology settings within the cancer Treatment Phase.
C Yosefy - One of the best experts on this subject based on the ideXlab platform.
-
Effects of low-dose aspirin on blood pressure and endothelial function of treated hypertensive hypercholesterolaemic subjects
Journal of Human Hypertension, 2005Co-Authors: E Magen, J R Viskoper, J Mishal, R Priluk, D London, C YosefyAbstract:The main objective of this study was to assess whether aspirin 100 mg QD can improve blood pressure (BP) control and endothelial function in subjects with arterial hypertension (AH) and hypercholesterolaemia. In total, 21 patients of both sexes (52.1±11.5 years) with treated AH and hypercholesterolaemia on antihypertensive and statin therapy were included in the Treatment group. In the control group, 20 matched patients of both sexes (51.3±12.7 years), but without statin therapy, were recruited. Treatment group subjects received aspirin (100 mg QD) for a duration of 12 weeks at randomization ( Treatment Phase-1 ), followed by single blind matching placebo for 12 weeks ( Placebo Phase ) and then again received aspirin (100 mg QD) for an additional 12 weeks ( Treatment Phase-2 ). The control group participated in Treatment Phase-1, but did not continue Placebo Phase and Treatment Phase-2. At randomization and at the end of each study Phase, mean 24-h systolic BP (SBP) and diastolic BP (DBP) were assessed by 24-h ambulatory blood pressure monitoring (ABPM) and endothelium-dependent (flow mediated, FMD) and -independent (nitroglycerin induced, NTG) vasodilatations of brachial artery were measured using high-resolution ultrasound. In Treatment Phase-1, reduction of SBP and DBP (ΔSBP 5.7±2.6 mmHg, P =0.008; ΔDBP 3.8±1.7 mmHg, P =0.014) and improvement of FMD (4.1±0.6%, P =0.019), in Placebo Phase an elevation of SBP and DBP (ΔSBP −6.2±2.9 mmHg, P =0.002; ΔDBP −4.2±1.9 mmHg, P =0.031) and worsening of FMD (−3.8±0.9%, P =0.027), and in Treatment Phase-2 reduction of SBP and DBP (ΔSBP 4.9±2.3 mmHg, P =0.005; ΔDBP 4.1±1.3 mmHg, P =0.024) and improvement of FMD (4.5±1.3%, P =0.009) were observed in the Treatment Group but not in the control group. Addition of low-dose aspirin to antihypertensive medications and statins in hypertensive and hypercholesterolaemic subjects can reduce both SBP and DBP by improvement of endothelial function.
-
Effects of low-dose aspirin on blood pressure and endothelial function of treated hypertensive hypercholesterolaemic subjects.
Journal of human hypertension, 2005Co-Authors: E Magen, J R Viskoper, J Mishal, R Priluk, D London, C YosefyAbstract:The main objective of this study was to assess whether aspirin 100 mg QD can improve blood pressure (BP) control and endothelial function in subjects with arterial hypertension (AH) and hypercholesterolaemia. In total, 21 patients of both sexes (52.1+/-11.5 years) with treated AH and hypercholesterolaemia on antihypertensive and statin therapy were included in the Treatment group. In the control group, 20 matched patients of both sexes (51.3+/-12.7 years), but without statin therapy, were recruited. Treatment group subjects received aspirin (100 mg QD) for a duration of 12 weeks at randomization (Treatment Phase-1), followed by single blind matching placebo for 12 weeks (Placebo Phase) and then again received aspirin (100 mg QD) for an additional 12 weeks (Treatment Phase-2). The control group participated in Treatment Phase-1, but did not continue Placebo Phase and Treatment Phase-2. At randomization and at the end of each study Phase, mean 24-h systolic BP (SBP) and diastolic BP (DBP) were assessed by 24-h ambulatory blood pressure monitoring (ABPM) and endothelium-dependent (flow mediated, FMD) and -independent (nitroglycerin induced, NTG) vasodilatations of brachial artery were measured using high-resolution ultrasound. In Treatment Phase-1, reduction of SBP and DBP (DeltaSBP 5.7+/-2.6 mmHg, P=0.008; DeltaDBP 3.8+/-1.7 mmHg, P=0.014) and improvement of FMD (4.1+/-0.6%, P=0.019), in Placebo Phase an elevation of SBP and DBP (DeltaSBP -6.2+/-2.9 mmHg, P=0.002; DeltaDBP -4.2+/-1.9 mmHg, P=0.031) and worsening of FMD (-3.8+/-0.9%, P=0.027), and in Treatment Phase-2 reduction of SBP and DBP (DeltaSBP 4.9+/-2.3 mmHg, P=0.005; DeltaDBP 4.1+/-1.3 mmHg, P=0.024) and improvement of FMD (4.5+/-1.3%, P=0.009) were observed in the Treatment Group but not in the control group. Addition of low-dose aspirin to antihypertensive medications and statins in hypertensive and hypercholesterolaemic subjects can reduce both SBP and DBP by improvement of endothelial function.
Feras Hawari - One of the best experts on this subject based on the ideXlab platform.
-
Smoking cessation care can translate to lower hazard of death in the short-run in cancer patients - a retrospective cohort study to demonstrate the value of smoking cessation services within the Treatment Phase of cancer
BMC cancer, 2019Co-Authors: Feras Hawari, N. A. Obeidat, Dalia Rimawi, K. JamalAbstract:Smoking cessation is a key step towards improving cancer care and outcomes. However, smoking cessation interventions are underprovided in oncology settings. Within Jordan’s only comprehensive oncology center, we sought to evaluate receipt of care at a smoking cessation clinic and the effect of assisted abstinence through the smoking cessation clinic on short-term (two-year) survival after a cancer diagnosis. We employed a retrospective cohort study design. Cancer registry and smoking cessation clinic data for adult Jordanian cancer patients diagnosed between 2009 and 2016, who also were cigarette smokers, and who received full Treatment at King Hussein Cancer Center, were analyzed. Specifically, descriptive statistics of patients who visited the smoking cessation clinic were generated, and short-term (two-year) hazard of death of patients based on whether or not smoking cessation clinic-assisted abstinence occurred, were evaluated. There were 3403 patients who met our inclusion criteria. Approximately 21% of cancer patients were seen at the smoking cessation clinic, and significant demographic and clinical disparities in who was being seen [at the smoking cessation clinic] existed. In 2387 patients with available survival data, smokers who never went to the smoking cessation clinic (or were seen only once, or seen a year or more from diagnosis) had a hazard of death 2.8 times higher than smokers who had visited the smoking cessation clinic and who also confirmed they had not smoked on atleast two of their 3-, 6- or 12-month follow-up visits (95% confidence interval [CI] = 1.7–4.6). Non-abstainers at the smoking cessation clinic exhibited a similar disadvantage (HR 2.7, 95% CI 1.4–5.0). Although evidence-based smoking cessation interventions increase the likelihood of abstinence and can lower the short-term hazard of death during cancer Treatment, there is a deprioritization of smoking cessation interventions during cancer care, as indicated by low proportions of patients seen at the smoking cessation clinic. Our findings emphasize the importance of promoting interventions to avail smoking cessation interventions in oncology settings within the cancer Treatment Phase.
E Magen - One of the best experts on this subject based on the ideXlab platform.
-
Effects of low-dose aspirin on blood pressure and endothelial function of treated hypertensive hypercholesterolaemic subjects
Journal of Human Hypertension, 2005Co-Authors: E Magen, J R Viskoper, J Mishal, R Priluk, D London, C YosefyAbstract:The main objective of this study was to assess whether aspirin 100 mg QD can improve blood pressure (BP) control and endothelial function in subjects with arterial hypertension (AH) and hypercholesterolaemia. In total, 21 patients of both sexes (52.1±11.5 years) with treated AH and hypercholesterolaemia on antihypertensive and statin therapy were included in the Treatment group. In the control group, 20 matched patients of both sexes (51.3±12.7 years), but without statin therapy, were recruited. Treatment group subjects received aspirin (100 mg QD) for a duration of 12 weeks at randomization ( Treatment Phase-1 ), followed by single blind matching placebo for 12 weeks ( Placebo Phase ) and then again received aspirin (100 mg QD) for an additional 12 weeks ( Treatment Phase-2 ). The control group participated in Treatment Phase-1, but did not continue Placebo Phase and Treatment Phase-2. At randomization and at the end of each study Phase, mean 24-h systolic BP (SBP) and diastolic BP (DBP) were assessed by 24-h ambulatory blood pressure monitoring (ABPM) and endothelium-dependent (flow mediated, FMD) and -independent (nitroglycerin induced, NTG) vasodilatations of brachial artery were measured using high-resolution ultrasound. In Treatment Phase-1, reduction of SBP and DBP (ΔSBP 5.7±2.6 mmHg, P =0.008; ΔDBP 3.8±1.7 mmHg, P =0.014) and improvement of FMD (4.1±0.6%, P =0.019), in Placebo Phase an elevation of SBP and DBP (ΔSBP −6.2±2.9 mmHg, P =0.002; ΔDBP −4.2±1.9 mmHg, P =0.031) and worsening of FMD (−3.8±0.9%, P =0.027), and in Treatment Phase-2 reduction of SBP and DBP (ΔSBP 4.9±2.3 mmHg, P =0.005; ΔDBP 4.1±1.3 mmHg, P =0.024) and improvement of FMD (4.5±1.3%, P =0.009) were observed in the Treatment Group but not in the control group. Addition of low-dose aspirin to antihypertensive medications and statins in hypertensive and hypercholesterolaemic subjects can reduce both SBP and DBP by improvement of endothelial function.
-
Effects of low-dose aspirin on blood pressure and endothelial function of treated hypertensive hypercholesterolaemic subjects.
Journal of human hypertension, 2005Co-Authors: E Magen, J R Viskoper, J Mishal, R Priluk, D London, C YosefyAbstract:The main objective of this study was to assess whether aspirin 100 mg QD can improve blood pressure (BP) control and endothelial function in subjects with arterial hypertension (AH) and hypercholesterolaemia. In total, 21 patients of both sexes (52.1+/-11.5 years) with treated AH and hypercholesterolaemia on antihypertensive and statin therapy were included in the Treatment group. In the control group, 20 matched patients of both sexes (51.3+/-12.7 years), but without statin therapy, were recruited. Treatment group subjects received aspirin (100 mg QD) for a duration of 12 weeks at randomization (Treatment Phase-1), followed by single blind matching placebo for 12 weeks (Placebo Phase) and then again received aspirin (100 mg QD) for an additional 12 weeks (Treatment Phase-2). The control group participated in Treatment Phase-1, but did not continue Placebo Phase and Treatment Phase-2. At randomization and at the end of each study Phase, mean 24-h systolic BP (SBP) and diastolic BP (DBP) were assessed by 24-h ambulatory blood pressure monitoring (ABPM) and endothelium-dependent (flow mediated, FMD) and -independent (nitroglycerin induced, NTG) vasodilatations of brachial artery were measured using high-resolution ultrasound. In Treatment Phase-1, reduction of SBP and DBP (DeltaSBP 5.7+/-2.6 mmHg, P=0.008; DeltaDBP 3.8+/-1.7 mmHg, P=0.014) and improvement of FMD (4.1+/-0.6%, P=0.019), in Placebo Phase an elevation of SBP and DBP (DeltaSBP -6.2+/-2.9 mmHg, P=0.002; DeltaDBP -4.2+/-1.9 mmHg, P=0.031) and worsening of FMD (-3.8+/-0.9%, P=0.027), and in Treatment Phase-2 reduction of SBP and DBP (DeltaSBP 4.9+/-2.3 mmHg, P=0.005; DeltaDBP 4.1+/-1.3 mmHg, P=0.024) and improvement of FMD (4.5+/-1.3%, P=0.009) were observed in the Treatment Group but not in the control group. Addition of low-dose aspirin to antihypertensive medications and statins in hypertensive and hypercholesterolaemic subjects can reduce both SBP and DBP by improvement of endothelial function.
Xiangyang Liu - One of the best experts on this subject based on the ideXlab platform.
-
Releasing and Freezing Phase Separation of Polyvinyl Alcohol/Silica To Control Polymorphs of Silica
Crystal Growth & Design, 2015Co-Authors: Jieyang Huang, Longbo Luo, Huina Wang, Xu Wang, Yan Feng, Xiangyang LiuAbstract:Crystalline silica is prepared beyond 1500 °C in a traditional process. Here, we prepared both cristobalite-rich and quartz-rich silica by calcinating polyvinyl alcohol (PVA)/silica films at 900 °C. Results of characterizations show that polymorphisms of silica were dependent on the Phase separation of PVA and silica before calcinations. The Phase separation is controlled by a coagulation bath. By soaking PVA/silica hybrid films in a coagulation bath before thermal Treatment, Phase separation of PVA and silica was frozen and prevented. When PVA/silica hybrid films were not soaked in a coagulation bath before thermal Treatment, Phase separation of PVA and silica was released. Further research reveals that different Phase structures of PVA and silica generate distinct microscopical morphologies and molecular structures of silica, leading to variation of the final polymorphs.
